Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Endocrine Therapy and a CDK 4/6 inhibitor|DRUG: Endocrine Therapy and a CDK 4/6 inhibitor
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins